FrancophonIA/ELRC3.0 huggingface dataset:
English: The data on ispaghula husk support therefore the use of ispaghula seed as a laxative.The effectiveness of ispaghula seed in softening stools is based on its laxative effects and no specific data are available.
Estonian: Kõrbeteelehe seemne efektiivsus rooja pehmendamisel põhineb selle lahtistaval toimel ja sellekohased üksikasjalikud andmed puuduvad.
English: Information on the use and licensing of ispaghula seed medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab teavet kõrbe-teelehe seemet sisaldava ravimi kasutamise ja müügiloa kohta riiklikult ravimiametilt.
English: Side effects have been reported with ispaghula seed medicines, including flatulence and abdominal distension (swelling of the belly).
Estonian: Kõrbe-teelehe seemet sisaldavate ravimite kasutamisel on teatatud kõrvalnähtudest nagu kõhupuhitus ja kõhu paisumine .
English: At the same time ispaghula seed lubricates the intestine which improves the transit of stools.
Estonian: Samal ajal libestab kõrbe-teelehe seeme soolestikku, hõlbustades rooja liikumist.
English: Levetiracetam Teva levetiracetam
Estonian: Levetiracetam Teva levetiratsetaam
English: What measures are being taken to ensure the safe and effective use of Levetiracetam Teva?
Estonian: Mis meetmed võetakse, et tagada Levetiracetam Teva ohutu ja efektiivne kasutamine?
English: The full EPAR for Levetiracetam Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Levetiracetam Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The exact way in which levetiracetam works is still unclear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells.
Estonian: Levetiratsetaami täpne toimemehhanism ei ole teada, kuid see seondub sünapsipõiekeste valguga 2A, mis osaleb närvirakkudest keemiliste virgatsainete vabastamisel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Teva on 26 August 2011.
Estonian: Euroopa Komisjon andis Levetiracetam Teva müügiloa, mis kehtib kogu Euroopa Liidus, 26. augustil
English: • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to be inherited).
Estonian: • primaarsed generaliseerunud toonilised-kloonilised episoodid (rasked epilepsiaepisoodid, millega kaasneb ka teadvusekaotus) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mida peetakse pärilikuks).
English: Other information about Levetiracetam Teva
Estonian: Muu teave Levetiracetam Teva kohta
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Levetiracetam Teva have been included in the summary of product characteristics and the package leaflet.
Estonian: Levetiracetam Teva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Levetiracetam Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Levetiracetam Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Patients unable to swallow should be given a solution containing levetiracetam.
Estonian: Neelamisraskustega patsientidele tuleb anda levetiratsetaami sisaldavat lahust.
English: The Committee recommended that Levetiracetam Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Levetiracetam Teva müügiloa.
English: What is Levetiracetam Teva?
Estonian: Mis on Levetiracetam Teva?
English: Levetiracetam Teva tablets are swallowed with liquid.
Estonian: Levetiracetam Teva tabletid neelatakse koos vedelikuga.
English: This helps Levetiracetam Teva to stabilise electrical activity in the brain and prevent seizures.
Estonian: See aitab Levetiracetam Teval stabiliseerida aju elektrilist talitlust ning ennetada epilepsiaepisoode.
English: This is a summary of the European public assessment report (EPAR) for Levetiracetam Teva.
Estonian: See on ravimi Levetiracetam Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: This means that Levetiracetam Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Estonian: See tähendab, et Levetiracetam Teva on sarnane võrdlusravimiga Keppra, millel juba on Euroopa Liidus müügiluba.
English: Because Levetiracetam Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Levetiracetam Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab Levetiracetam Teva kasulikkus sellega kaasnevad riskid.
English: When Levetiracetam Teva is added to another epilepsy treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Estonian: Levetiracetam Teva lisamisel teisele epilepsiaravimile vähemalt 12-aastastel patsientidel kehamassiga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
English: The CHMP concluded that, in accordance with EU requirements, Levetiracetam Teva has been shown to have comparable quality and to be bioequivalent to Keppra.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Levetiracetam Teva võrdväärne kvaliteet ja bioekvivalentsus ravimiga Keppra.
English: Levetiracetam Teva can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Estonian: Levetiracetam Tevat tohib kasutada ainsa ravimina vähemalt 16-aastastel epilepsia esmadiagnoosiga patsientidel, et ravida sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode.
English: Levetiracetam Teva is a medicine that contains the active substance levetiracetam.
Estonian: Levetiracetam Teva on ravim, mis sisaldab toimeainena levetiratsetaami.
English: Levetiracetam Teva is a ‘generic medicine'.
Estonian: Levetiracetam Teva on geneeriline ravim.
English: Levetiracetam Teva can also be used as an add-on to other epilepsy medicines to treat:
Estonian: Levetiracetam Tevat tohib kasutada ka teiste epilepsiaravimite lisaravimina, et ravida järgmisi haigusseisundeid:
English: Why has Levetiracetam Teva been approved?
Estonian: Miks Levetiracetam Teva heaks kiideti?
English: For patients weighing less than 50 kg, the dose depends on body weight.
Estonian: Alla 25 kg kehamassiga laste soovitatav annus oleneb kehamassist.
English: Because Levetiracetam Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Estonian: Et Levetiracetam Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Levetiracetam Teva bioekvivalentsust võrdlusravimiga Keppra.
English: The active substance in Levetiracetam Teva, levetiracetam, is an epilepsy medicine.
Estonian: Levetiracetam Teva toimeaine levetiratsetaam on epilepsiaravim.
English: When Levetiracetam Teva is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Estonian: Levetiracetam Teva kasutamisel ainsa ravimina on algannus 250 mg kaks korda ööpäevas.
English: How is Levetiracetam Teva used?
Estonian: Kuidas Levetiracetam Teva toimib?
English: What are the benefits and risks of Levetiracetam Teva?
Estonian: Milles seisneb Levetiracetam Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: How has Levetiracetam Teva been studied?
Estonian: Kuidas Levetiracetam Tevat uuriti?
English: What is Levetiracetam Teva used for?
Estonian: Milleks Levetiracetam Tevat kasutatakse?
English: The medicine can only be obtained with a prescription.
Estonian: Levetiracetam Teva on retseptiravim.
English: EU/1/19/1365/001 Cufence
Estonian: EU/1/19/1365/001
English: Bottle (glass)
Estonian: Pudel (klaas)
English: 100 capsules
Estonian: 100 kapslit
English: 200 mg Capsule, hard
Estonian: 200 mg Kõvakapslid Suukaudne
English: Oral use
Estonian: Cufence
English: These trials are briefly described below.
Estonian: Neid uuringuid on lühidalt kirjeldatud allpool.
English: Ask your hospital pharmacist how to throw away medicines you no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: There was no increased benefit thereafter, up to 1 year.
Estonian: Hilisemat lisanduvat kasu ei täheldatud kuni 1 aasta jooksul.
English: Date of first authorisation: 11th January 2016
Estonian: Müügiloa esmase väljastamise kuupäev: 11th Jaanuar 2016
English: Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby.
Estonian: Öelge oma arstile, kui te olete rase, arvate end olevat rase või kavatsete rasestuda.
English: EARLY-ACS trial
Estonian: EARLY-ACS uuring
English: Please tell your doctor if you have had any of these conditions.
Estonian: Palun informeerige oma arsti, kui teil on esinenud nimetatud seisundeid.
English: Wessling Hungary Kft Fòti ùt 56, Budapest 1047, Hungary
Estonian: Wessling Hungary Kft Fòti ùt 56, Budapest 1047, Ungari
English: This recommendation is based on pharmacodynamic and pharmacokinetic data.
Estonian: See soovitus põhineb farmakodünaamilistel ja farmakokineetilistel andmetel.
English: 30 days
Estonian: 30 päeva
English: The carcinogenic potential of eptifibatide has not been evaluated in long-term studies.
Estonian: Eptifibatiidi kantserogeenset potentsiaali ei ole pikaajalistes uuringutes hinnatud.
English: Arterial procedures
Estonian: Arteriaalsed protseduurid
English: • or increased CK-MB.
Estonian: • või CK-MB aktiivsuse tõus.
English: It is not recommended for use in children and adolescents below 18 years of age, due to a lack of data on safety and efficacy.
Estonian: Ravimit ei soovitata kasutada lastel ja noorukitel vanuses alla 18 aasta ohutuse ja efektiivsuse andmete puudumise tõttu.
English: This product is for hospital use only.
Estonian: Käesolev preparaat on ette nähtud ainult haiglas kasutamiseks.
English: MI was identified per the CK-MB core laboratory criteria.
Estonian: MI identifitseeriti laboratoorsete CK-MB põhikriteeriumite alusel.
English: Particularly:
Estonian: Eriti:
English: Monitor these patients closely with regard to bleeding.
Estonian: Jälgige neid patsiente verejooksu suhtes hoolikalt.
English: These are absolute reporting frequencies without taking into account placebo rates.
Estonian: Need on absoluutsed teatamissagedused, mille puhul ei ole arvesse võetud platseebo puhul teatatud sagedusi.
English: - sudden, severe allergic reaction.
Estonian: - järsku tekkiv tõsine allergiline reaktsioon.
English: The first bolus and the infusion were started simultaneously, immediately before the PCI procedure and were followed by a second bolus 10 minutes after the first.
Estonian: Esimest boolust ja infusiooni alustati samaaegselt, kohe pärast PCI protseduuri ning sellele järgnes teine boolus 10 minutit pärast esimest.
English: The extent of eptifibatide binding to human plasma protein is about 25 %.
Estonian: Eptifibatiidi sidumise tase inimese plasma proteiinidega on ligikaudu 25 %.
English: A target aPTT of 50-70 seconds was recommended.
Estonian: Soovitatav eesmärk oli saavutada aPPT 50...70 sekundit.
English: The undesirable effects are listed by body system and frequency.
Estonian: Kõrvaltoimed on loetletud organsüsteemi ja esinemissageduse järgi.
English: Eptifibatide p-Value
Estonian: Eptifibatiid p-väärtus
English: The available clinical evidence cannot however confirm that this dose modification results in a preserved benefit (see section 5.1).
Estonian: Kuid saadaolevad kliinilised kogemused ei kinnita, et see annuse modifitseerimine tooks kaasa ravist saadava kasu säilimise (vt lõik 5.1).
English: Very rarely, bleeding has become severe and even fatal.
Estonian: Väga harva võib verejooks kulgeda raskelt ja lõppeda isegi surmaga.
English: In the absence of compatibility studies, Eptifibatide Accord must not be mixed with other medicinal products except those mentioned in 6.6.
Estonian: Sobivusuuringute puudumise tõttu ei tohi Eptifibatide Accord'i segada teiste ravimitega, välja arvatud nendega, mis on loetletud lõigus 6.6.
English: No formal pharmacokinetic interaction studies have been conducted.
Estonian: Formaalseid farmakokineetilisi koostoime uuringuid ei ole läbi viidud.
English: The activated partial thromboplastin time (aPTT) must be monitored in order to maintain a value between 50 and 70 seconds, above 70 seconds there may be an increased risk of bleeding.
Estonian: Aktiveeritud osalist tromboplastiini aega (aPTT) tuleb jälgida, et hoida seda vahemikus 50 kuni 70 sekundit; aeg üle 70 sekundi võib suurendada verejooksude riski.
English: MI could also be reported following CEC adjudication of an investigator report.
Estonian: MI võidi ka arvesse võtta pärast komitee otsuse langetamist uurija raporti kohta.
English: Warnings and precautions
Estonian: Hoiatused ja ettevaatusabinõud :
English: To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist or nurse if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription.
Estonian: Võimalike koostoimete vältimiseks teatage oma arstile, haigla apteekrile või meditsiiniõele, kui te võtate või olete hiljuti võtnud või kavatsete võtta mis tahes muid ravimeid, sh ilma retseptita saadavaid ravimeid,
English: Other potential bleeding sites such as central and peripheral nervous system and retroperitoneal sites, must be carefully considered too.
Estonian: Samuti tuleb mõelda teistele potentsiaalsetele verejooksu kohtadele nagu tsentraalne ja perifeerne närvisüsteem ning retroperitoneaalruum.
English: − Eptifibatide Accord is not intended for use in children or adolescents less than 18 years of age.
Estonian: − Eptifibatide Accord ei ole ette nähtud kasutamiseks alla 18-aastastel lastel või noorukitel.
English: Similar results were also obtained for the 2 secondary endpoints assessed at 30 days: a triple composite of death, MI and UTVR, and the more robust combination of death and MI.
Estonian: Sarnased tulemused saadi ka kahe sekundaarse tulemusnäitaja puhul, mida hinnati 30 päeva pärast: kolmest komponendist - surm, MI ja UTVR - koosnev tulemusnäitaja või surma ja MI kombinatsioon.
English: Potentially, an overdose of eptifibatide could result in bleeding.
Estonian: Potentsiaalselt võib eptifibatiidi üleannustamine viia verejooksu tekkimisele.
English: This leaflet was last revised in <{MM/YYYY}>.
Estonian: Infoleht on viimati uuendatud: <{KK/AAAA}>.
English: Thus, changes in laboratory parameters associated with bleeding (e.g. bleeding time) are common and expected.
Estonian: Seega on verejooksuga seotud laboratoorsete näitajate (nt veritsusaeg) muutused sagedased ja eeldatavad.
English: Bleeding is most common at the arterial access site in patients undergoing percutaneous arterial procedures.
Estonian: Verejooks on kõige tavalisem arteriaalse juurdepääsutee kohas patsientidel, kellele tehakse perkutaanseid arteriaalseid protseduure.
English: Other events that may occur in patients, who require this type of treatment, include those that are related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, shock or cardiac arrest.
Estonian: Teised seda tüüpi ravi vajavatel patsientidel tekkida võivad kõrvaltoimed on seotud seisundiga, mida teil ravitakse (näiteks kiire või ebaregulaarne südametegevus, madal vererõhk, šokk või südameseiskus).
English: Not relevant, as Eptifibatide Accord is intended for use only in hospitalised patients.
Estonian: Pole asjakohane, sest Eptifibatide Accord on ette nähtud ainult haiglas kasutamiseks.
English: Store in a refrigerator(2°C - 8°C).
Estonian: Hoida külmkapis (2°C…8°C).
English: Before using, inspect the vial contents.
Estonian: Enne kasutamist kontrollida viaali sisaldist.
English: Eptifibatide -treated patients who had a prothrombin time (PT) > 14.5 seconds and received warfarin concomitantly did not appear to be at an increased risk of bleeding.
Estonian: Eptifibatiidiga ravitud patsientidel, kelle protrombiini aeg (PT) oli > 14,5 sekundit ja kes said samaaegselt varfariini, ei esinenud suuremat verejooksude riski.
English: Consequently these studies are not suitable to evaluate the toxicity of eptifibatide on reproductive function (see section 4.6).
Estonian: Seetõttu ei saa nende alusel hinnata eptifibatiidi toksilisust reproduktiivsele funktsioonile (vt lõik 4.6).
English: If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute.
Estonian: Kui te põete neeruhaigust, võidakse infusiooniannust vähendada kuni 1 mikrogrammi/kg/minutis.
English: Emergency or semi-elective surgery
Estonian: Erakorraline või pool-plaaniline operatsioon
English: This means that it helps to prevent blood clots from forming.
Estonian: See tähendab, et ravim aitab vältida verehüüvete tekkimist.
English: The majority of adverse reactions experienced by patients treated with eptifibatide were generally related to bleeding or to cardiovascular events that occur frequently in this patient population.
Estonian: Enamik eptifibatiidiga ravitud patsientidel esinevatest kõrvaltoimetest olid üldiselt seotud verejooksude või kardiovaskulaarsete komplikatsioonidega, mis esinevad selles patsientide populatsioonis sageli.
English: This should be taken into consideration by patients on a controlled sodium diet.
Estonian: Seda tuleb arvestada patsientide puhul, kes on kontrollitud naatriumisisaldusega dieedil.
English: Eptifibatide Accord should not be used during pregnancy unless clearly necessary.
Estonian: Eptifibatide Accord'i ei tohi kasutada raseduse ajal, kui see ei ole hädavajalik.
English: It is usually given with aspirin and unfractionated heparin.
Estonian: Tavaliselt manustatakse seda koos aspiriini ja fraktsioneerimata hepariiniga.
English: The data sources used to determine adverse reaction frequency descriptors included two phase III clinical studies (PURSUIT and ESPRIT).
Estonian: Andmed kõrvaltoimete esinemissageduse kohta saadi kahest III faasi kliinilisest uuringust (PURSUIT ja ESPRIT).
English: In the PURSUIT trial, there were 9 patients who received bolus and/or infusion doses more than double the recommended dose, or who were identified by the investigator as having received an overdose.
Estonian: PURSUIT uuringus oli 9 patsienti, kes said booluse ja/või infusiooni soovitatud annusest vähemalt kaks korda suuremas annuses või kes identifitseeriti uurija poolt kui üleannuse saanud patsient.
English: - if you have been treated with another medicine of the same type as Eptifibatide Accord.
Estonian: − kui teid on ravitud mõne muu sama tüüpi ravimiga kui Eptifibatide Accord.
English: Note that causality has not been determined for all adverse reactions.
Estonian: Teadke, et kõikide kõrvaltoimete puhul ei ole kindlaks tehtud põhjuslikku seost.
English: Consequently the use of Eptifibatide Accord is not recommended in these circumstances (see section 4.5).
Estonian: Seetõttu ei soovitata nende seisundite korral Eptifibatide Accord'i kasutada (vt lõik 4.5).
English: You must also be given doses of aspirin and heparin (if not contraindicated in your case).
Estonian: Teile võidakse manustada ka aspiriini ja hepariini (kui see ei ole teile vastunäidustatud).
English: Other medicines and Eptifibatide Accord
Estonian: Muud ravimid ja Eptifibatide Accord
English: Table 1: Incidence of Death/CEC-Assessed MI («Treated as Randomised» Population)
Estonian: Tabel 1: Surmajuhtude / komitee poolt hinnatud MI esinemissagedus («Vastavalt randomiseerimisele ravitud» populatsioon)
English: Reproduction studies in animal species where eptifibatide shows a similar pharmacologic activity as in humans are not available.
Estonian: Reproduktsiooniuuringud loomaliikidel, kellel eptifibatiid on samasuguse farmakoloogilise aktiivsusega kui inimesel, ei ole kättesaadaval.
English: Women, the elderly, patients with low body weight or with moderate renal impairment (creatinine clearance > 30 - < 50 ml/min) may have an increased risk of bleeding.
Estonian: Naissoost, eakatel ja väikese kehakaalu või mõõduka neerukahjustusega (kreatiniini kliirens > 30...< 50 ml/min) patsientidel võib esineda suurem verejooksu risk.
English: − if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section
Estonian: kui olete allergiline eptifibatiidi või selle ravimi mis tahes koostisosade (loetletud lõigus 6)
English: GUSTO severe/life threatening bleeding was uncommon and comparable in both treatment groups (0.8 %).
Estonian: GUSTO tõsist/eluohtlikku verejooksu esines harva ja see oli võrreldav mõlemas ravirühmas (0,8%).
English: − if you had a major operation or severe injury during the past 6 weeks.
Estonian: − kui teil on viimase 6 nädala jooksul olnud suur operatsioon või tõsine vigastus.
English: - prothrombin time > 1.2 times control, or International Normalized Ratio (INR) ≥ 2.0
Estonian: − protrombiini aeg > 1,2 korra kontrollajast suurem või INR ≥ 2,0
English: If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period.
Estonian: Kui imetate last, tuleb ravi ajaks imetamine katkestada.
English: When administered alone, eptifibatide has no measurable effect on prothrombin time (PT) or activated partial thromboplastin time (aPTT).
Estonian: Eptifibatiit üksi manustatuna ei avaldanud mõõdetavat toimet protrombiini ajale (PT) või aktiveeritud osalisele tromboplastiini ajale (aPTT).
English: Stop heparin administration if the ACT exceeds 300 seconds; do not administer until the ACT falls below 300 seconds.
Estonian: Hepariini manustamine lõpetada, kui aktiveeritud hüübivusaeg ületab 300 sekundit; mitte manustada hepariini enne, kui see langeb alla 300 sekundi.
English: There was no excessive bleeding in any of these patients, although one patient undergoing CABG surgery was reported as having had a moderate bleed.
Estonian: Ühelgi neist patsientidest ei esinenud rasket verejooksu, kuigi ühe patsiendi puhul, kellele tehti koronaararterite šunteerimine, teatati mõõdukast verejooksust.
English: The reduction in the incidence of endpoint events in patients receiving eptifibatide appeared early during treatment (within the first 72-96 hours) and this reduction was maintained through 6 months, without any significant effect on mortality.
Estonian: Tulemusnäitaja esinemissagedus vähenes eptifibatiidi saavatel patsientidel ravi varases järgus (esimese 72...96 tunni jooksul) ja vähenemine püsis 6 kuu jooksul ilma oluliselt suremust mõjutamata.
English: Eptifibatide Accord is not compatible with furosemide.
Estonian: Eptifibatide Accord ei sobi kokku furosemiidiga.